Category: Invacare Corp.
Ohio medical device maker Invacare posts some major ups and downs in its Q3 financials, but net losses that blow away expectations get a rise from Wall Street.
Invacare (NYSE:IVC) got a rise from Wall Street after releasing its 3rd-quarter earnings report, posting deep losses in sales and continuing earnings that nonetheless beat analysts' estimates.
Shares of medical device maker Invacare slip after the company restates its Q2 financial report with deeper losses, but shares claw back some of their lost value after Invacare reports a divestiture of its Champion Manufacturing division.
Invacare gains a few points on Wall Street despite sinking sales and widening losses as the company sees the light at the end of an FDA consent decree effectively shutting down 2 company facilities.
The FDA gave Invacare the green-light to resume some research & development activities functions at 2 of its facilities in Elyria, Ohio.
Invacare (NYSE:IVC) is allowed to resume design activities at HQ and a Taylor Street facility in Elyria, Ohio, after the FDA gave the company a partial go-ahead following a manufacturing shut-down last year.
Invacare says it can resume limited manufacturing at a plant in Ohio that was shut down by the FDA last year.
Invacare (NYSE:IVC) said the FDA gave it permission to begin limited manufacturing at a plant in Elyria, Ohio, that the federal watchdog agency shut down last year.
The Healthcare Supply Chain Assn. names 45 medical device companies it says are shifting the cost of the 2.3% federal excise tax, among them Allergan and Invacare.
Invacare manages a swing to 2012 black despite what CEO Gerald Blouch called 1 of "the most challenging" in the company's history.
Invacare (NYSE:IVC) weathered what CEO Gerald Blouch called "1 of the most challenging in the company's history" and managed to eke out a small profit.